Research ArticleOriginal Article
Open Access

The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome

Basil O. Saleh, Wasan F. Ibraheem and Nada S. Ameen
Saudi Medical Journal May 2015, 36 (5) 562-567; DOI: https://doi.org/10.15537/smj.2015.5.11112

References

  1. ↵
    1. Carmina E,
    2. Azziz R
    (2006) Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 86(Supp 1):S7–S8.
    OpenUrlPubMed
  2. ↵
    1. Aflatoonian A,
    2. Seyedhassani SM,
    3. Tabibnejad N
    (2009) The epidemiological and etiological aspects of infertility in Yazd province of Iran. Iranian Journal of Reproductive Medicine 7:117–122.
    OpenUrl
  3. ↵
    1. Azziz R,
    2. Carmina E,
    3. Dewailly D,
    4. Diamanti-Kandarakis E,
    5. Escobar-Morreale HF,
    6. Futterweit W,
    7. et al.
    (2006) Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237–4245.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Itman C,
    2. Mendis S,
    3. Barakat B,
    4. Loveland LK
    (2006) All in the family: TGF-β family action in testis development. Reproduction 132:233–236.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Visser JA,
    2. de Jong FH,
    3. Laven JS,
    4. Themmen AP
    (2006) Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 131:1–9.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. La Marca A,
    2. Sighinolfi G,
    3. Radi D,
    4. Argento C,
    5. Baraldi E,
    6. Artenisio AC,
    7. et al.
    (2009) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16:113–130.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Bako AU,
    2. Morad S,
    3. Atiomo WA
    (2005) Polycystic ovary syndrome: an overview. Reviews in Gynaecological Practice 5:115–122.
    OpenUrl
  8. ↵
    1. Pellatt L,
    2. Hanna L,
    3. Brincat M,
    4. Galea R,
    5. Brain H,
    6. Whitehead S,
    7. Mason H
    (2007) Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 92:240–245.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Pigny P,
    2. Jonard S,
    3. Robert Y,
    4. Dewailly D
    (2006) Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91:941–945.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Wiweko B,
    2. Maidarti M,
    3. Priangga MD,
    4. Shafira N,
    5. Fernando D,
    6. Sumapraja K,
    7. et al.
    (2014) Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet 31:1311–1316.
    OpenUrl
  11. ↵
    1. Lee DE,
    2. Park SY,
    3. Park SY,
    4. Lee SR,
    5. Chung HW,
    6. Jeong K
    (2014) Clinical and biochemical profiles according to Homeostasis Model Assessment-insulin Resistance (HOMA-IR) in Korean women with polycystic ovary syndrome. J Menopausal Med 20:104–110.
    OpenUrl
  12. ↵
    1. Boomsma CM,
    2. Fauser BC,
    3. Macklon NS
    (2008) Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 26:72–84.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Li R,
    2. Yu G,
    3. Yang D,
    4. Li S,
    5. Lu S,
    6. Wu X,
    7. et al.
    (2014) Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross-sectional study. BMC Endocr Disord 14:76.
    OpenUrl
  14. ↵
    1. Johnson NP
    (2014) Metformin use in women with polycystic ovary syndrome. Ann Transl Med 2:56–63.
    OpenUrl
  15. ↵
    1. Nestler JE
    (2008) Metformin in the treatment of infertility in PCOS: an alternative perspective. Fertil Steril 90:14–16.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Neagu M,
    2. Cristescu C
    (2012) Anti-Műllerian hormone -- a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life 5:462–464.
    OpenUrl
  17. ↵
    1. Nestler JE
    (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358:47–54.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Tan S,
    2. Hahn S,
    3. Benson S,
    4. Dietz T,
    5. Lahner H,
    6. Moeller LC,
    7. et al.
    (2007) Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 157:669–676.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Badawy A,
    2. Elnashar A
    (2011) Treatment options for polycystic ovary syndrome. Int J Womens Health 3:25–35.
    OpenUrlPubMed
  20. ↵
    1. Azziz R,
    2. Carmina E,
    3. Dewailly D,
    4. Diamanti-Kandarakis E,
    5. Escobar-Morreale HF,
    6. Futterweit W,
    7. et al.
    (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kricka LJ
    (2000) Interferences in immunoassay-still a threat. Clin Chem 46:1037–1038.
    OpenUrlFREE Full Text
  22. ↵
    1. Groome NP,
    2. Evans LW
    (2000) Does measurement of inhibin have a clinical role?Ann Clin Biochem, 37:419–431.
  23. ↵
    1. Burits CA,
    2. Ashwood ER,
    3. Bruns DE
    , eds (2008) Tietz Fundamentals of Clinical Chemistry, 735-801 (Saunders Elsevier, St. Louis (MO)), 6th ed, pp 373–401.
  24. ↵
    1. Carlsson IB,
    2. Scott JE,
    3. Visser JA,
    4. Ritvos O,
    5. Themnen AP,
    6. Hovatta O
    (2006) Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 21:2223–2227.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. La Marca A,
    2. Volpe A
    (2006) Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?Clin Endocrinol (Oxf), 64:603–610.
  26. ↵
    1. Catteau-Jonard S,
    2. Jamin SP,
    3. Leclerc A,
    4. Gonzalès J,
    5. Dewailly D,
    6. di Clemente N
    (2008) Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:4456–4461.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Chen MJ,
    2. Yang WS,
    3. Chen CL,
    4. Wu MY,
    5. Yang YS,
    6. Ho HN
    (2008) The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with the polycystic ovary syndrome. Hum Reprod 23:952–957.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Fleming R,
    2. Harborne L,
    3. MacLaughlin DT,
    4. Ling D,
    5. Norman J,
    6. Sattar N,
    7. et al.
    (2005) Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 83:130–136.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Tomova A,
    2. Deepinder F,
    3. Robeva R,
    4. Kirilov G,
    5. Mechandjiev Z,
    6. Kumanov P
    (2011) Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res 43:723–727.
    OpenUrlPubMed
  30. ↵
    1. Grigoryan O,
    2. Absatarova J,
    3. Andreeva E,
    4. Melnichenko G,
    5. Dedov I
    (2014) Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol 66:85–89.
    OpenUrl
  31. ↵
    1. Nascimento AD,
    2. Silva Lara LA,
    3. Japur de Sá Rosa-e-Silva AC,
    4. Ferriani RA,
    5. Reis RM
    (2013) Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol 29:246–249.
    OpenUrl
  32. ↵
    1. Bayrak A,
    2. Terbell H,
    3. Urwitz-Lane R,
    4. Mor E,
    5. Stanczyk FZ,
    6. Paulson RJ
    (2007) Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 87:870–875.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Carlsen SM,
    2. Vanky E,
    3. Fleming R
    (2009) Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 24:1732–1738.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Richard SL,
    2. Ricardo A
    (2003) Androgen excess disorders. Danforth’s Obstetrics and Gynecology (Lippincott Williams &Wilkins, Philadelphia (PA)), 8th ed, pp 663–672.
  35. ↵
    1. Welt CK,
    2. Taylor AE,
    3. Martin KA,
    4. Hall JE
    (2002) Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. J Clin Endocrinol Metab 87:5559–5565.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Palomba S,
    2. Falbo A,
    3. Russo T,
    4. Orio F,
    5. Tolino A,
    6. Zullo F
    (2010) Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 25:1005–1013.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Nardo LG,
    2. Yates AP,
    3. Roberts SA
    (2009) The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 24:2917–2923.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Begawy AF,
    2. El-Mazny AN,
    3. Abou-Salem NA,
    4. El-Taweel NE
    (2010) Anti-mullerian hormone in polycystic ovary syndrome and normo-ovulatory women: correlation with clinical, hormonal and ultrasonographic parameters. Middle East Fertility Society Journal 15:253–258.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section